Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Octreotide
Drug ID BADD_D02412
Description Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.[L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.[L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.[L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).[L14513] In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.[L14495,L14507,L14528]
Indications and Usage Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors.[L14513] The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and [lanreotide].[L14507]
Marketing Status approved; investigational
ATC Code H01CB02
DrugBank ID DB00104
KEGG ID D00442
MeSH ID D015282
PubChem ID 448601
TTD Drug ID D02XIY
NDC Product Code 73301-004; 35207-0002; 69880-120; 52416-118; 52416-109; 62147-0206; 41524-0007
UNII RWM8CCW8GP
Synonyms Octreotide | SMS 201-995 | SMS 201 995 | SMS 201995 | SM 201-995 | SM 201 995 | SM 201995 | Sandoz 201-995 | Sandoz 201 995 | Sandoz 201995 | Compound 201-995 | Compound 201 995 | Compound 201995 | SAN 201-995 | SAN 201 995 | SAN 201995 | Octreotide Acetate | Octreotide Acetate Salt | Sandostatine | Sandostatin
Chemical Information
Molecular Formula C49H66N10O10S2
CAS Registry Number 79517-01-4
SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4= CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal pain20.02.03.0030.000279%-
Respiratory arrest22.02.01.0090.000186%-
Respiratory disorder22.02.07.0020.000186%-
Respiratory failure14.01.04.003; 22.02.06.002--
Restlessness17.02.05.021; 19.11.02.0020.000466%
Retching07.01.07.002---
Retinal detachment06.09.03.003; 12.01.04.004--
Retinal disorder06.08.03.005---
Retinal tear06.09.03.010; 12.01.04.014--
Rhinorrhoea22.12.03.0210.000876%
Rotator cuff syndrome12.01.07.018; 15.01.08.002--
Scab23.03.03.004---
Sciatica15.10.01.001; 17.10.03.0010.000186%-
Scoliosis15.10.04.001--
Second primary malignancy16.16.01.0140.001211%
Sensory disturbance17.02.07.006---
Sensory loss17.02.07.007---
Sinus bradycardia02.03.03.0090.000186%
Sinus congestion22.04.06.001---
Sinus headache17.14.01.002; 22.12.03.022--
Skin atrophy23.01.05.0010.000186%
Skin discolouration23.03.03.0050.000373%-
Skin disorder23.03.03.0070.000727%-
Skin exfoliation23.03.07.003---
Skin fragility23.03.03.009---
Skin hypertrophy23.01.04.002---
Skin irritation23.03.04.009---
Skin lesion23.03.03.010---
Skin reaction10.01.03.019; 23.03.03.0130.000503%-
Skin ulcer23.07.03.003; 24.04.03.007--
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 25 Pages